Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

计划入组 325 人 · 首次发布于 2024 年 8 月 23 日

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

计划入组 367 人 · 首次发布于 2023 年 11 月 1 日

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

首次发布于 2024 年 6 月 5 日

CG0070

Cretostimogene Shows Promise in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Cretostimogene Shows High Complete Response Rate in BCG-Unresponsive Bladder Cancer

Urinary Genomic Analysis Predicts Response to Cretostimogene in Bladder Cancer Trial